相关实验视频
Updated: Jan 9, 2026

Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
在克罗恩病患者中,infliximab的最低水平和术后内镜复发之间的相关性
Zhenya Sun1, Zhenxin Zhu1, Ran Yang2
1Department of Colorectal Surgery, Center for Inflammatory Bowel Diseases.
较低的infliximab谷值与克罗恩病 (CD) 患者的术后内镜复发率较高有关. 保持足够的INFLIXIMAB水平可能是预防手术后疾病复发的关键.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病 (CD) 在手术后的复发率很高.
- 术后维持治疗对于预防CD复发至关重要.
- 在手术后因弗利西马布水平和复发之间的联系需要更多的研究.
研究的目的:
- 评估Infliximab的最低水平与克罗恩病患者的术后内镜复发之间的关联.
- 为了确定infliximab水平是否可以预测手术后的复发.
主要方法:
- 分析了137名接受因弗利克西马布治疗的术后CD患者.
- 测量了因弗利克西马布的血清最低度.
- 在3个月内进行了结肠镜检查,以评估内镜复发 (SES-CD ≥3或鲁特吉茨评分≥2).
主要成果:
- 在复发的患者中观察到较低的infliximab谷值 (3.4vs5.9μg/ml).
- 对于infliximab的最低水平,一个最佳的切割值是3.15μg/ml.
- 因弗利克西马布水平与内镜复发相反相关,特别是在大结肠切除后.
结论:
- 较低的infliximab最低水平与CD的术后内镜复发增加相关.
- 这种关联适用于整体手术队列和大结肠切除子组.
- 监测因弗利西马布水平可能有助于预防术后复发.
更多相关视频
07:06Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...